FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Lehrstuhl für Innere Medizin I (Medizin 1)
Overview
Publications
(275)
Research Grants
(4)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Engineering Therapeutic Regulatory T Cells to Overexpress G Protein-Coupled Receptor 15 Improves Functional Fitness for In Vivo Gut Homing (2025)
Müller T, Liu L, Wiesinger M, Atreya I, Atreya R, Bacher P, Becker C, et al.
Journal article, Letter
Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease (2025)
Bao L, Yu Y, Gonzalez Acera M, Patankar J, Gießl A, Sturm G, Kühl AA, et al.
Journal article
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial. (2025)
Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath M, et al.
Journal article
Treatment of severe flares in Crohn’s disease and ulcerative colitis Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa (2025)
Stallmach A, Stallhofer J, Schmidt C, Atreya R, Grunert PC
Journal article
Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study (2024)
Suzuki K, Sameshima Y, Yokoyama J, Terai S, Yoneyama H, Atreya R, Neurath M, et al.
Journal article
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials (2024)
Peyrin‐Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola , Jahnsen J, et al.
Journal article
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study (2024)
Fischer S, Donhauser M, Cohnen SE, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, et al.
Journal article
Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience (2024)
Wagner K, Müller T, Vitali F, Fischer S, Haberkamp S, Rouse-Merkel R, Atreya R, et al.
Journal article
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials (2024)
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, et al.
Journal article
Spatial Single Cell Profiling Using Imaging Mass Cytometry: Inflammatory Versus Penetrating Crohn's Disease (2024)
Lehmann M, Weixler B, Elezkurtaj S, Loddenkemper C, Atreya I, Atreya R, Bacher P, et al.
Journal article
‹
1
2
3
...
27
›